Research and Markets Releases COVID 19 Clinical Trials Insight

Research and Markets has added The "Global Coronavirus COVID 19 Clinical Trials Insight 2020" to its reporting.

Number of Drugs in Clinical Trials: >30 Drugs
Majority of Drugs in Research Phase: >15 Drugs
USA & China Dominating Clinical Trials: >20 Drugs
Vaccines Accounts Major Share in Clinical Trials: >10 Vaccines
Expected Market Opportunity: >U.S. $ 1 Billion

Since the recent outbreak of the virus at the global level, research fields at all levels have focused their work on developing a vaccine that will be effective against the mechanism of the coronavirus by which it is escaping all the commercially available vaccines for virus.

On an average, more than 30 clinical trials are being conducted at the global level, with hundreds of patients enrolled. Of the 30 clinical trials that have been initiated, only few have cleared the early stages of development, with a few set to begin Phase III trials.

The outbreak of the virus has led advancement in the partnership for technological support. By observing the number of the patients and the healthcare management all the world, it is expected that the very first therapy against the virus will be launched by next year in 2021.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.